432 related articles for article (PubMed ID: 15170361)
1. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.
Carrasco R; Smith JA; Lovell D
Paediatr Drugs; 2004; 6(3):137-46. PubMed ID: 15170361
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic use of "biologics" in inflammatory joint and spinal diseases].
Seitz M
Ther Umsch; 2002 Oct; 59(10):535-43. PubMed ID: 12428439
[TBL] [Abstract][Full Text] [Related]
3. [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies].
Sautner J; Leeb BF
Wien Med Wochenschr; 2003; 153(13-14):304-8. PubMed ID: 12924105
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
[TBL] [Abstract][Full Text] [Related]
5. Biologic therapies for juvenile arthritis.
Wilkinson N; Jackson G; Gardner-Medwin J
Arch Dis Child; 2003 Mar; 88(3):186-91. PubMed ID: 12598373
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review.
Shenoi S; Wallace CA
Paediatr Drugs; 2010 Dec; 12(6):367-77. PubMed ID: 21028916
[TBL] [Abstract][Full Text] [Related]
7. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.
Weisman MH
J Rheumatol Suppl; 2002 Sep; 65():33-8. PubMed ID: 12236621
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.
Lovell DJ; Giannini EH; Reiff A; Jones OY; Schneider R; Olson JC; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Lange M; Finck BK; Burge DJ;
Arthritis Rheum; 2003 Jan; 48(1):218-26. PubMed ID: 12528122
[TBL] [Abstract][Full Text] [Related]
9. Etanercept in juvenile rheumatoid arthritis.
Johnson CJ; Reilly KM; Murray KM
Ann Pharmacother; 2001 Apr; 35(4):464-71. PubMed ID: 11302411
[TBL] [Abstract][Full Text] [Related]
10. Current treatment of juvenile rheumatoid arthritis.
Ilowite NT
Pediatrics; 2002 Jan; 109(1):109-15. PubMed ID: 11773549
[TBL] [Abstract][Full Text] [Related]
11. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.
Culy CR; Keating GM
Drugs; 2002; 62(17):2493-537. PubMed ID: 12421111
[TBL] [Abstract][Full Text] [Related]
12. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.
Fleishmann RM
Clin Exp Rheumatol; 2002; 20(5 Suppl 27):S35-41. PubMed ID: 14989428
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons.
Nixon R; Bansback N; Brennan A
Rheumatology (Oxford); 2007 Jul; 46(7):1140-7. PubMed ID: 17478472
[TBL] [Abstract][Full Text] [Related]
14. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study.
Lahdenne P; Vähäsalo P; Honkanen V
Ann Rheum Dis; 2003 Mar; 62(3):245-7. PubMed ID: 12594111
[TBL] [Abstract][Full Text] [Related]
15. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
16. Molecular differences in anticytokine therapies.
Calabrese LH
Clin Exp Rheumatol; 2003; 21(2):241-8. PubMed ID: 12747285
[TBL] [Abstract][Full Text] [Related]
17. Juvenile rheumatoid arthritis: therapeutic perspectives.
Chikanza IC
Paediatr Drugs; 2002; 4(5):335-48. PubMed ID: 11994038
[TBL] [Abstract][Full Text] [Related]
18. Etanercept therapy in children with juvenile rheumatoid arthritis.
Hung JJ; Huang JL
J Microbiol Immunol Infect; 2005 Dec; 38(6):444-6. PubMed ID: 16341346
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
20. [Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects].
Botsios C; Ostuni P; Sfriso P; Furlan A; Fiocco U; Sgarabotto D; Todesco S
Reumatismo; 2003; 55(4):224-35. PubMed ID: 14872221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
